Saidi Skender, Stavridis Sotir, Stankov Oliver, Dohcev Sasho, Panov Sasho
.
Pril (Makedon Akad Nauk Umet Odd Med Nauki). 2017 Sep 1;38(2):123-129. doi: 10.1515/prilozi-2017-0030.
An increasing tendency has recently emerged for the use of phytotherapeutic agents as alternative to commercial pharmacological agents for the treatment of benign prostate hyperplasia (BPH). The purpose of this study is to evaluate the effects of Serenoa repens alcohol extract treatment on BPH patients' symptoms and major parameters during one-year follow-up. The study was performed on 70 men aged 40 - 79 years (mean 60.58) with symptomatic BPH that were divided into a group of 40 patients treated with Serenoa repens extract (SRT) and a control group of 30 patients that received no treatment and were observed only. The following parameters were determined at the time of diagnosis (baseline), and after 6 and 12 months: prostate size, serum prostate-specific antigen (PSA) and uroflowmetry parameters including maximum flow rate (MFR), average flow rate (AFR) and post-voiding residual volume (PVRV). In addition, the relevant patient symptoms were evaluated using the International Prostate Symptom Score (IPSS) system. The patients in the SRT group showed a statistically significant increment of the average MFR and AFR values and reduction of PV relative to the control group (p<0.05). The significant differences between the proportion of patients with prostate volume >40 ml in the SRE treated group vs. control group was observed (p<0.05). The mean IPSS score was highly significantly reduced in the SRT group (p<0.01). The mild improvements of the urine flow, prostate size and IPSS score during 12 months treatment with the Serenoa repens extract indicate possible efficiency of this phytotherapeutic agent in patients with BPH.
最近,使用植物治疗剂替代商业药理剂治疗良性前列腺增生(BPH)的趋势日益明显。本研究的目的是评估锯叶棕乙醇提取物治疗对BPH患者症状和主要参数在一年随访期间的影响。该研究对70名年龄在40 - 79岁(平均60.58岁)有症状的BPH男性进行,分为40例接受锯叶棕提取物治疗(SRT)的患者组和30例未接受治疗仅进行观察的对照组。在诊断时(基线)以及6个月和12个月后测定以下参数:前列腺大小、血清前列腺特异性抗原(PSA)和尿流率参数,包括最大尿流率(MFR)、平均尿流率(AFR)和排尿后残余尿量(PVRV)。此外,使用国际前列腺症状评分(IPSS)系统评估相关患者症状。与对照组相比,SRT组患者的平均MFR和AFR值有统计学显著增加,PV降低(p<0.05)。观察到锯叶棕提取物治疗组与对照组中前列腺体积>40 ml的患者比例存在显著差异(p<0.05)。SRT组的平均IPSS评分显著降低(p<0.01)。锯叶棕提取物治疗12个月期间尿流、前列腺大小和IPSS评分的轻度改善表明这种植物治疗剂对BPH患者可能有效。